Short Interest in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Decreases By 78.7%

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the recipient of a significant decrease in short interest in April. As of April 30th, there was short interest totaling 13,319 shares, a decrease of 78.7% from the April 15th total of 62,619 shares. Based on an average trading volume of 42,961 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.1% of the shares of the stock are short sold.

Genenta Science Stock Performance

Shares of GNTA stock traded down $0.01 during trading hours on Friday, hitting $0.62. 28,086 shares of the company’s stock were exchanged, compared to its average volume of 721,322. The stock’s 50-day moving average is $0.72 and its 200-day moving average is $1.26. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.16 and a quick ratio of 14.16. Genenta Science has a 52 week low of $0.55 and a 52 week high of $10.00.

Genenta Science (NASDAQ:GNTA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.28.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genenta Science in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Genenta Science

Several hedge funds have recently added to or reduced their stakes in the company. SmartHarvest Portfolios LLC boosted its holdings in Genenta Science by 656.1% in the first quarter. SmartHarvest Portfolios LLC now owns 134,447 shares of the company’s stock valued at $90,000 after acquiring an additional 116,666 shares during the last quarter. Weiss Asset Management LP bought a new position in Genenta Science during the fourth quarter worth about $480,000. Ghisallo Capital Management LLC bought a new position in Genenta Science during the fourth quarter worth about $482,000. Alyeska Investment Group L.P. bought a new position in Genenta Science during the fourth quarter worth about $328,000. Finally, Norges Bank bought a new position in Genenta Science during the fourth quarter worth about $337,000. Institutional investors own 15.13% of the company’s stock.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.